This Week in Cardiology Jul 18 2025 This Week in Cardiology
13 snips
Jul 18, 2025 Discover the latest on finerenone's FDA approval for heart failure and the complexities of choosing between TAVI and surgical AVR for aortic stenosis. Dive into the risks of catheter ablation, including brain lesions and visual migraines, as revealed by the TRAVERSE trial. The discussion also evaluates the impacts of atrial fibrillation treatments on brain health. With critiques of recent studies and a hopeful look at healthcare policy reforms, there's a wealth of engaging insights for healthcare professionals.
AI Snips
Chapters
Transcript
Episode notes
Finerenone's Modest Benefit in HF-PEF
- Finerenone showed a 16% reduction in heart failure events in HF-PEF but no mortality benefit.
- Spironolactone remains first line; finerenone's benefit is modest and cost-effectiveness is unclear.
Carbon Footprint Should Not Guide TAVI Choice
- TAVI has about half the carbon footprint of SAVR, mainly due to shorter ICU stay.
- Carbon footprint differences are trivial compared to other human activities and should not influence patient care.
LV Ablation Access Choice Remains Unclear
- The TRAVERSE trial found fewer brain lesions with transeptal LV ablation but results are fragile and clinically unclear.
- Choosing LV access should prioritize procedural success, not uncertain brain injury data.